Anthem Biosciences (ANTHEM) Stock Overview
Operates as technology-focused contract research, development, and manufacturing organization. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ANTHEM from our risk checks.
ANTHEM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Anthem Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹759.25 |
| 52 Week High | ₹873.50 |
| 52 Week Low | ₹701.90 |
| Beta | 0 |
| 1 Month Change | -7.82% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANTHEM | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -2.8% | 1.8% | 1.5% |
| 1Y | n/a | -0.4% | -4.7% |
Return vs Industry: Insufficient data to determine how ANTHEM performed against the Indian Life Sciences industry.
Return vs Market: Insufficient data to determine how ANTHEM performed against the Indian Market.
Price Volatility
| ANTHEM volatility | |
|---|---|
| ANTHEM Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: ANTHEM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: Insufficient data to determine ANTHEM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1,963 | Ajay Bhardwaj | anthembio.com |
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry.
Anthem Biosciences Limited Fundamentals Summary
| ANTHEM fundamental statistics | |
|---|---|
| Market cap | ₹426.40b |
| Earnings (TTM) | ₹5.05b |
| Revenue (TTM) | ₹20.52b |
Is ANTHEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANTHEM income statement (TTM) | |
|---|---|
| Revenue | ₹20.52b |
| Cost of Revenue | ₹8.66b |
| Gross Profit | ₹11.86b |
| Other Expenses | ₹6.82b |
| Earnings | ₹5.05b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.99 |
| Gross Margin | 57.81% |
| Net Profit Margin | 24.59% |
| Debt/Equity Ratio | 4.7% |
How did ANTHEM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 09:10 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anthem Biosciences Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bansi Desai | J.P. Morgan |